BDBM127817 US10758542, Example 190::US8791123, 190::US9782415, Example 190::US9796724, Example 190

SMILES Cc1ncc(F)cc1C1CCCN1c1ccn2ncc(C(=O)NC3(C)CC3)c2n1

InChI Key InChIKey=OXVCBPXLNVQEGM-UHFFFAOYSA-N

Data  25 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 25 hits for monomerid = 127817   

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMAssay Description:Trk enzymatic selectivity was assessed using Omnia Kinase Assay reagents from Invitrogen Corp. Enzyme (either TrkA or TrkB from Invitrogen Corp.) and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Tyk2: Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mix...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [781-1124](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Jak3: Compounds of Formula I were screened for their ability to inhibit Jak3 using the general enzyme inhibition assay method, in which the assay mix...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Jak2: Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mix...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [866-1154](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Jak1: Compounds of Formula I were screened for their ability to inhibit Jak1 using the general enzyme inhibition assay method, in which the assay mix...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMAssay Description:Trk enzymatic selectivity was assessed using Omnia Kinase Assay reagents from Invitrogen Corp. Enzyme (either TrkA or TrkB from Invitrogen Corp.) and...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Jak2: Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mix...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMAssay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [781-1124](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [866-1154](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [808-1132](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMpH: 7.5Assay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2014
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [886-1187](Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMAssay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 2.40nMAssay Description:An enzyme-linked immunosorbant assay (ELISA) was used to assess TrkA kinase activity in the presence of inhibitors. Immulon 4HBX 384-well microtiter ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2019
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2014
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2014
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2014
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Array Biopharma

US Patent
LigandPNGBDBM127817(US8791123, 190 | US9782415, Example 190 | US979672...)
Affinity DataIC50: 1.00E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Jak2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/22/2014
Entry Details
Go to US Patent